Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13754453 | 0.83 | CA2 (0.50) | CA2CA1CA5ACA9CA5B | |
| SCHEMBL3078988 | 0.78 | CA2 (0.61) | CA2 | |
| SCHEMBL15083519 | 0.77 | CA1 (0.42) | CA2CA1CA5ACA9CA5B | |
| SCHEMBL11290860 | 0.77 | CA2 (0.80) | CA2 | |
| SCHEMBL28218223 | 0.76 | CA2 (0.59) | CA2 | |
| SCHEMBL14822340 | 0.76 | TPH1 (0.42) | CA2CA1CA5ACA9CA5B | |
| SCHEMBL29002854 | 0.76 | PTGS2 (0.50) | TP53CYP51A1 | |
| SCHEMBL15042744 | 0.75 | NOS1 (0.52) | CA2CA1CA5ACA9CA5B | |
| SCHEMBL29145318 | 0.74 | TP53 (0.42) | CA2CA1CA5ACA9CA5B | |
| SCHEMBL20553240 | 0.74 | CA1 (0.48) | CA2CA1CA5ACA9CA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | CA2 2606/4885CA1 1794/4885CA5A 1836/4885 |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | CA2 2606/4885CA1 1794/4885CA5A 1836/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | CA2 3768/4885CA1 2393/4885CA5A 1033/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | CA2 2606/4885CA1 1794/4885CA5A 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.